Neogenomics Stock Investor Sentiment

NEO Stock  USD 17.73  0.17  0.95%   
About 56% of NeoGenomics' investor base is looking to short. The analysis of overall sentiment of trading NeoGenomics stock suggests that many investors are alarmed at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

NeoGenomics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards NeoGenomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over a year ago at zacks.com         
NeoGenomics Upgraded to Strong Buy What Does It Mean for the Stock?
zacks News
over a year ago at thelincolnianonline.com         
NeoGenomics Epigenomics Critical Survey
news
over a year ago at news.google.com         
NeoGenomics shareholder returns have been respectable, earning 70 percent in 1 year - Simply Wall St
Google News at Macroaxis
over a year ago at simplywall.st         
NeoGenomics shareholder returns have been respectable, earning 70 percent in 1 year
Simply Wall St News at Macroaxis
over a year ago at thelincolnianonline.com         
Louisiana State Employees Retirement System Acquires 8,100 Shares of NeoGenomics, Inc.
news
over a year ago at news.google.com         
Investors in NeoGenomics have unfortunately lost 69 percent over the last three years - Yahoo Financ...
Google News at Macroaxis
over a year ago at globenewswire.com         
Mydecine Innovations Group Announces Listing on the Canadian Securities Exchange and Delisting from ...
Macroaxis News: globenewswire.com
over a year ago at businesswire.com         
Canada Jetlines Announces Closing of First Tranche of 13.5 Million Equity Financing
businesswire News
over a year ago at finance.yahoo.com         
Investors in NeoGenomics have unfortunately lost 69 percent over the last three years
Yahoo News
over a year ago at thelincolnianonline.com         
NeoGenomics, Inc. Receives 19.18 Average PT from Brokerages
news
over a year ago at news.google.com         
Liquid Biopsy Products Market Growth, Developments Analysis and ... - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
Global Clinical Laboratory Services Market Will Surpass USD 207. Billion by 2030 at 4.8 percent CAGR...
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Global Crypto Exchange PayBito Adds NEO, EGLD, and APT to Its Coin List
Yahoo News
over a year ago at news.google.com         
Market for Bioinformatics could reach 88.88 billion by 2032 - Benzinga
Google News at Macroaxis
over a year ago at finance.yahoo.com         
NEO Battery Materials Announces Temporary TSXV Trading Halt for Change of Business Completion into a...
Yahoo News
Far too much social signal, news, headlines, and media speculation about NeoGenomics that are available to investors today. That information is available publicly through NeoGenomics media outlets and privately through word of mouth or via NeoGenomics internal channels. However, regardless of the origin, that massive amount of NeoGenomics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NeoGenomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeoGenomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeoGenomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeoGenomics alpha.

NeoGenomics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Wall Street Analysts Believe NeoGenomics Could Rally 51.29 percent Heres is How to Trade
11/04/2024
2
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
11/08/2024
3
Disposition of 11336 shares by Hannah Alison L. of NeoGenomics subject to Rule 16b-3
11/15/2024
4
Segall Bryant Hamill LLC Has 27.93 Million Holdings in NeoGenomics, Inc.
11/20/2024
5
NeoGenomics Inc Shares Up 4.09 percent on Nov 22
11/22/2024
6
NEO Battery Materials Announces Corporate Webinar on Silicon Anode Technology Developments Pathway to Commercialization
11/25/2024
7
Disposition of 6224 shares by Warren Stone of NeoGenomics subject to Rule 16b-3
11/29/2024
8
NEO SPACE GROUP TO ACQUIRE UP42 EARTH OBSERVATION DIGITAL PLATFORM FROM AIRBUS
12/03/2024
9
Brokerages Set NeoGenomics, Inc. PT at 20.25
12/05/2024
10
Disposition of 11746 shares by Sherman Jeffrey Scott of NeoGenomics subject to Rule 16b-3
12/06/2024
11
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
12/09/2024
12
NeoGenomics Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
12/11/2024
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.61)
Revenue Per Share
5.098
Quarterly Revenue Growth
0.104
Return On Assets
(0.03)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.